In preclinical CRC models, KRAS mutations increased the expression of amino acid transporters via the hippo pathway effector YAP1, resulting in mTOR activation and subsequent CRC cell proliferation [25]. This evidence concerns the gene SLC38A7 and colorectal carcinoma.